Twist Bioscience, the San Francisco startup that makes synthetic DNA used in genetically modified foods and pharmaceutical drugs, is the latest Bay Area biotech firm gearing up to go public. The company, founded in 2013 and based in the city’s Mission Bay neighborhood, on Tuesday filed a form S-1 saying it plans to raise up to $86.3 million in an initial public offering.

Biotech startup that sells ‘made to order’ DNA plans to go public

The San Francisco Chronicle is the Bay Area’s premier news source, providing an authoritative voice that lends context and depth to the conflicts and changes that shape the region. Our coverage aims to make readers feel smarter about the important issues of the day. Beats are covered through the prisms of change, conflict and power, without losing sight of the quirky and eclectic stories that make the Bay Area unique.     A SpokenEdition transforms written content into human-read audio you can listen to anywhere. It's perfect for times when you can’t read - while driving, at the gym, doing chores, etc. Find more at www.spokenedition.com

Business

Technology

The San Francisco Chronicle is the Bay Area’s premier news source, providing an authoritative voice that lends context and depth to the conflicts and changes that shape the region. Our coverage aims to make readers feel smarter about the important issues of the day. Beats are covered through the prisms of change, conflict and power, without losing sight of the quirky and eclectic stories that make the Bay Area unique. A SpokenEdition transforms written content into human-read audio you can listen to anywhere. It's perfect for times when you can’t read - while driving, at the gym, doing chores, etc. Find more at www.spokenedition.com

Share Biotech startup that sells ‘made to order’ DNA plans to go public

Sign up to save your podcasts

Biotech startup that sells ‘made to order’ DNA plans to go public

Biotech startup that sells ‘made to order’ DNA plans to go public